323990.KQ
Vaxcell-Bio Therapeutics Co., Ltd.
KOE · Healthcare · Biotechnology · KR
KRW 4,490.00
−10.56%Year over year
Reported trailing growth
- Revenue
- +17.3%
- EBITDA
- —
- EBIT
- -3.2%
- EPS
- -21.2%
- Free cash flow
- -72.5%
- Operating cash flow
- -11.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +2167.6%
- EBITDA
- -50.1%
- EBIT
- -3.7%
- Net income
- -25.6%
- EPS
- -24.7%
- Free cash flow
- -12.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026